Physician

Michael Patrick Wolbert, M.D.

According to 2025 Medicare claims, Michael Wolbert, M.D. (NPI: 1881711778) practices allergy/immunology in the Midland, TX market, with the plurality of this provider's patient population coming from Midland, TX. This provider's primary affiliated billing organization is WEST TEXAS ALLERGY, PA (NPI: 1073631404; TIN: 75-2781652) and primary practice location at 79707-2753.

Wolbert's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 300 traditional Medicare patients, billed 19,087 HCPCS/CPT codes, and received $253,957 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 865 prescription claims across 208 beneficiaries totaling $739,687 in drug costs, led by Dupixent Syringe (Dupilumab). DME data shows 362 claims. Open Payments data shows 100 records totaling $26,941. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $96,490 to $253,957. Similarly, Part D prescription costs have moved sharply higher in recent years, from $190,226 to $739,687. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $8,863 and ending at $11,510.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	309	10,682	$96,490
2016	306	11,843	$106,302
2017	334	12,225	$114,080
2018	338	15,714	$131,144
2019	337	15,120	$134,498
2020	320	13,699	$118,804
2021	572	16,412	$171,252
2022	368	16,765	$160,568
2023	355	20,813	$246,713
2024	300	19,087	$253,957

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	217	903	$190,226
2016	213	1,045	$200,728
2017	245	1,153	$396,555
2018	274	1,229	$380,310
2019	272	1,133	$473,743
2020	247	967	$452,614
2021	266	1,002	$490,672
2022	262	934	$611,440
2023	238	869	$798,234
2024	208	865	$739,687

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	136	$6,876
2016	N/R	104	$4,870
2017	N/R	135	$3,328
2018	N/R	166	$62,386
2019	N/R	228	$30,400
2020	N/R	238	$99,503
2021	N/R	355	$187,479
2022	N/R	358	$303,104
2023	N/R	408	$388,909
2024	N/R	362	$368,269

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	140	221	$79
94060	Test to measure expiratory airflow and volume changes before and after medication administration	63	74	$25
95165	Professional service for preparation and provision of 1 or more antigens	131	4,403	$9
95117	Professional service for multiple injections of allergen	92	1,543	$7
96160	Administration and interpretation of patient-focused health risk assessment	57	80	$2

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Dupixent Syringe	Dupilumab	47	1,316	$184,861
Cuvitru	Immun Glob G(Igg)/Gly/Iga Ov50	33	924	$158,905
Nucala	Mepolizumab	24	672	$81,814
Fasenra Pen	Benralizumab	12	672	$64,321
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	60	2,040	$42,516

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1555	Injection, immune globulin (cuvitru), 100 mg	N	N/R	40	$163,219
J1575	Injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immuneglobulin	N	N/R	13	$104,795
J1559	Injection, immune globulin (hizentra), 100 mg	N	N/R	16	$50,591
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	N	N/R	13	$25,126
J7677	Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram	N	N/R	13	$9,651

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	100	$26,941	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Michael Patrick Wolbert, M.D.?

Tedicare shows public-source Medicare data for Michael Patrick Wolbert, M.D. (NPI 1881711778), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Michael Patrick Wolbert, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Michael Patrick Wolbert, M.D.?

Michael Patrick Wolbert, M.D. is linked to WEST TEXAS ALLERGY, PA (billing NPI 1073631404) in the available physician profile data.

Does Michael Patrick Wolbert, M.D. have Open Payments data?

Michael Patrick Wolbert, M.D. has 100 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.